The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Phase III Trial of Doxorubicin With or Without Cisplatin in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study
Abstract
Purpose: Doxorubicin and cisplatin have activity in endometrial carcinoma and at initiation of this study ranked as the most active agents. This trial of stage III, IV, or recurrent disease evaluated whether combining these agents increases response rate (RR) and prolongs progression-free survival (PFS) and overall survival (OS) over doxorubicin alone. Patients and Methods: Of 299 patients registered, 281 (94%) were eligible. Regimens were doxorubicin 60 mg/m 2 intravenously or doxorubicin 60 mg/m 2 plus cisplatin 50 mg/m 2 every 3 weeks until disease progression, unacceptable toxicity, or a total of 500 mg/m 2 doxorubicin. Results: There were 12 (8%) complete (CR) and 26 (17%) partial responses (PR) among 150 patients receiving doxorubicin versus 25 (19%) CRs and 30 (23%) PRs among patients receiving the combination. The overall response rate was higher among patients receiving the combination (42%) compared with patients receiving doxorubicin (25%; P = .004). Median PFS was 5.7 and 3.8 months, respectively, for the combination and single agent. The PFS hazard ratio was 0.736 (95% CI, 0.577 to 0.939; P = .014). Median OS was 9.0 and 9.2 months, respectively, for the combination and single agent. Overall death rates were similar in the two groups (hazard ratio, 0.928; 95% CI, 0.727 to 1.185). Nausea, vomiting, and hematologic toxicities were common. The combination produced more grade 3 to 4 leukopenia (62% v 40%), thrombocytopenia (14% v 2%), anemia (22% v 4%), and nausea/vomiting (13% v 3%). Conclusion: Adding cisplatin to doxorubicin in advanced endometrial carcinoma improves RR and PFS with a negligible impact on OS and produces increased toxicity. These results have served as a building block for subsequent phase III trials in patients with disseminated and high-risk limited endometrial carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Fleming, G. F., Brunetto, V. L., Cella, D., Look, K. Y., Reid, G. C., Munkarah, A. R., Kline, R., Burger, R. A., Goodman, A., & Burks, R. T. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.184 · Cited by 565
Self-citationThigpen, J. T., Blessing, J. A., Homesley, H. D., Creasman, W. T., & Sutton, G. P. (1989) · Gynecologic Oncology · doi:10.1016/0090-8258(89)90605-7 · Cited by 148
Self-citationGallion, H. H., Brunetto, V. L., Cibull, M. L., Lentz, S. S., Reid, G. C., Soper, J. T., Burger, R. A., & Andersen, W. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.083 · Cited by 118
Self-citationThigpen, T., Vance, R. B., & Khansur, T. (1995) · PubMed · Cited by 62
Methotrexate in Advanced Endometrial Carcinoma
Muss, H. B., Blessing, J. A., Hatch, K. D., Soper, J. T., Webster, K. D., & Kemp, G. M. (1990) · American Journal of Clinical Oncology · doi:10.1097/00000421-199002000-00016 · Cited by 17
Cited by
Aggregation-Induced Emission: Together We Shine, United We Soar!
Mei, J., Leung, N. L. C., Kwok, R. T. K., Lam, J. W. Y., & Tang, B. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00263 · Cited by 8,270
Amant, F., Moerman, P., Neven, P., Timmerman, D., Van Limbergen, E., & Vergote, I. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67063-8 · Cited by 1,497
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
Colombo, N., Creutzberg, C., Amant, F., Bosse, T., González-Martín, A., Ledermann, J., Marth, C., Nout, R., Querleu, D., Mirza, M. R., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv484 · Cited by 1,386
Randall, M. E., Filiaci, V. L., Muss, H., Spirtos, N. M., Mannel, R. S., Fowler, J., Thigpen, J. T., & Benda, J. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.7617 · Cited by 872
Self-citationESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer
Colombo, N., Creutzberg, C., Amant, F., Bosse, T., Gonzalez-Martin, A., Ledermann, J., Marth, C., Nout, R., Querleu, D., Mirza, M. R., et al. (2016) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000609 · Cited by 767
Metadata
- Authors
- Thigpen, J. T., Brady, M. F., Homesley, H. D., Malfetano, J., DuBeshter, B., Burger, R. A., & Liao, S.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-10-01
- Volume
- 22
- Issue
- 19
- Pages
- 3902-3908
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2120965358
- Cited by
- 390
- References
- 6
- FWCI
- 23.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.